Prevention and control of viral hepatitis virus in Spain: Lessons learnt and the way forward

Madrid, November 23-24, 2006

Preliminary meeting conclusions
Objectives of the meeting

– Update of the epidemiological situation on viral hepatitis in Spain
– Overview of surveillance systems for infectious diseases with emphasis on hepatitis viruses and adverse events following vaccination in Spain
– Overview of the research activities on viral hepatitis in Spain
– Evaluation of current prevention and control measures on viral hepatitis in Spain
– Lessons learnt from the experience in Spain: successes, problems and barriers to overcome

Preliminary conclusions VHPB meeting Madrid 2006
Sequence of conclusions presentation

- Organization of health care system in Spain
- Surveillance systems
- Diagnostic tools and epidemiology of viral hepatitis
- Vaccination policies for hepatitis A&B
- Lessons learnt and challenges
Organization of health care system in Spain

• The Spanish National Health System:
  – Is based on public funding with universal free health services
  – is divided between State and Autonomous Community (AC) Health Departments (devolution)
  – is coordinated by the Inter-Territorial Board
  – the inter-Territorial Board makes recommendations (national consensus) but the ACs make decisions regarding health policies and vaccines procurement
  – MOH national consensus guarantees equal minimum health care standards;
  – Health care budget is allocated per capita to each AC. Individual ACs may decide on additional priorities within the budget.

Preliminary conclusions VHPB meeting Madrid 2006
Hepatitis epidemiological surveillance in Spain

• 3 main information systems (since 1995):
  – Statutory notification by GPs for Hep A&B. However, 5-10 times underreporting observed for Hep A in Catalonia
  – Microbiological information: Hep A, B&C (25% reporting coverage)
  – Outbreak reporting: Hep A, B&C

• Complementary systems:
  – Hospital discharge
  – Mortality surveillance
  – Seroepidemiological surveys
  – Special registries

Preliminary conclusions VHPB meeting Madrid 2006
Hepatitis outbreak investigation in Spain

• Outbreak investigation is part of national surveillance and a specific training program has been in place for 10 years

• Objectives:
  – Assess & confirm magnitude of outbreak
  – Identify source/vehicles
  – Identify risk factors/source of transmission

⇒ Recommended control measures: improved hygiene, enhanced surveillance, enhanced international cooperation

⇒ General recommendation to use vaccines but ACs make the decision

Preliminary conclusions VHPB meeting Madrid 2006
Molecular epidemiology of Hep A & E in Spain

- HAV detected in sewage, rivers & occasionally shellfish
- Most HAV isolates are of genotype 1A & 1B
- 6 HEV strains isolated from serum samples of patients with acute HEV (4 autochthonous & 1 imported; 1989-2003)
- Identification of HEV-RNA in 44% of sewage samples from Barcelona (genotype 3)
- Anti-HEV(IgG) antibodies identified in 19% of pigs in Catalonia (genotype 3)
- HEV virus strains detected in pigs could also be a source of infection for humans
- Both HAV and HEV isolates occasionally identified in the same sewage samples

Preliminary conclusions VHPB meeting Madrid 2006
Diagnosis of Hepatitis B

• Safety testing of blood donations in Spain includes compulsory HBsAg assay and of secondary importance anti-HBc Ab and ALT.
• Nucleic acid testing (NAT) technology is used in 80% of blood donations.
• Yield of HBV identification using NAT-technology ranges from 1:98,000 in the window phase and 1:24,000 in silent HBsAg-negative samples.
• Certain HBsAg mutants may be missed by some serological assay in blood donation testing.
• HBsAg mutants have been detected in HBsAg carriers but do not cause a measurable threat to the current vaccination policy.

Preliminary conclusions VHPB meeting Madrid 2006
Epidemiology of Hepatitis A & E in Spain

HAV
• Low endemicity with low rates of disease and very low mortality
• High % of <30-yr-olds not protected (<5% of 5-14yr-olds seropositive in Catalonia)
• High degree of detection of HAV in environment (tested in Catalonia)
• 2005: decreased incidence since 1997 but rise between 2002-2005 possibly due to immigration (study in Catalonia)
• In 2 communities (Melilla and Ceuta) with exceptionally high incidence rate initially, a significant decline of HAV incidence was demonstrated following implementation of immunization

HEV
• Anti-HEV prevalence is 7.3% in Catalonia, compared to 3-20% in industrialized countries
• similar HEV strains found in sewage samples and swine indicate that swine might be a reservoir for HEV in Spain

Preliminary conclusions VHPB meeting Madrid 2006
Hepatitis A outbreaks in Spain

- 1996-2003: 375 outbreaks; 2881 cases (107 outbreaks in Catalonia)
- Characteristics:
  - 15% foodborne (50% water/50% shellfish)
  - 70% direct transmission
  - significant number of cases in schools;
  - control measures reported for 235 outbreaks

Preliminary conclusions VHPB meeting Madrid 2006
Epidemiology of Hepatitis B in Spain

- Progressive decline in incidence of acute Hepatitis B in all Spain between 1997-2005 (47.3% fall)

Preliminary conclusions VHPB meeting Madrid 2006
Hepatitis C epidemiology in Spain

• HCV prevalence ranges from 1.5-2.5% in the general population of Spain (number of new infections dropped rapidly between 1996-2005)
• Up-to-date molecular tools are used for diagnosis of hepatitis C in Spain.
• In Spain, drug addiction is the most prevalent risk factor for HCV infection
• HCV prevalence is high in hemodialysed patients but Universal precaution and isolation measures have lead to the decrease of HCV infections
• Routes of transmission include IVDA, nosocomial infection, sexual transmission and vertical transmission
• Approximately 1/3 of HIV patients are co-infected with HCV

Preliminary conclusions VHPB meeting Madrid 2006
Hepatitis Vaccination policy in Spain

• Spanish National Immunization (NIS) guidelines are generally implemented in all ACs

• Recommended vaccines are free of charge and paid by ACs (HBV recommended for the entire country and HAV in 3 regions and high-risk groups)

• Most vaccines are given by paediatricians or in schools

• Some ACs provide additional vaccines (e.g. Hep A)

Preliminary conclusions VHPB meeting Madrid 2006
Hep A Vaccination in Spain

• 1993-1997: high risk-group vaccination (reviewed in 2004)
• 1998: Routine adolescent vaccination in Catalonia (combined Hep A/B vaccine, with estimated 98% effectiveness in 2005)
• 2000: Routine vaccination of children <2yrs in Ceuta and Melilla (based on epidemiology)

Preliminary conclusions VHPB meeting Madrid 2006
Hep B Vaccination in Spain

- 1983: high risk-group vaccination
- 1990: extended high risk-group list, including newborns of HBsAg+ mothers (reviewed again in 2004)
- 1992: efforts toward adolescent vaccination programmes
- 1996: adolescent (12-13yrs) vaccination in all ACs + newborn vaccination in some ACs
- 2003: infant vaccination in all ACs (now unified to 2,4,6-month schedule)+passive/active vaccination of newborns to HBsAg+mothers on 0,1,6-month schedule
- 2003: adolescent vaccination continued until children immunized reach adolescence
- 2005: >95% vaccination coverage for primary series in all ACs

Preliminary conclusions VHPB meeting Madrid 2006
Lessons learnt

• Preventive measures have led to a significant decrease in the incidence of Hepatitis A, B and C infections
• Up-to-date molecular tools are being used in Spain for identification of source of infection in nosocomial outbreaks
• Need to include HEV-RNA testing in investigation of acute/fulminant non-A, non-B, and non-C hepatitis, even in the absence of travel history
• HCV-positive cirrhosis of the liver has become a major cause for morbidity and mortality in HIV-positive patients
• Presence of a large cohort of HIV patients co-infected with HCV is expected to have an impact on the demand of health resources for clinical care

Preliminary conclusions VHPB meeting Madrid 2006
Challenges

• Strengthening of surveillance and reporting system for viral hepatitis;
  – Ensuring timely and complete case based reporting for all variables including laboratory confirmation
  – Analyzing data to define high risk groups and using for policy decisions and actions to further strengthen prevention and control efforts

• Sustaining immunization programme high performance and prioritizing high risk groups, including immigrants

• Data on the different therapeutic modalities used in Spain for treatment of HBV, HCV and co-infected patients, utilization and response rates were not presented

Preliminary conclusions VHPB meeting Madrid 2006